Prof. Hannu Alho MD, the organizer of Lightlake’s BED (Binge Eating Disorder) clinical trial, will
be giving presentations around the world this autumn telling about our
method for treating alcoholism with pharmacological extinction, including
the new data with nalmefene. The key point will be the reduction of harm
from alcohol abuse, as opposed to the traditional goal of total abstinence.
There has been a strong interest for a long time in harm reduction in the
field of alcoholism. It is by far the desired goal by nearly all
alcoholics, and now with the use of extinction using opioid antagonists, it
usually is a rather easily achieved goal.
His first presentation will be at the Sept 6-10 meeting of the
International Association of Addiction Medicine in Oslo, Norway. Prof.
Alho is President of ISAM. After that he will be talking in Budapest, then
Berlin, Bangkok, and finally Lisbon.
In his email to me, he stated that “we were the first in world” with
this harm reduction method of treatment. “It is becoming a hot topic, and
you get the credit!! You have been a good teacher for me!”

David Sinclair, PhD
--

......................................................
David Sinclair Ph.D
Chief Science Officer
Lightlake Therapeutics Inc.
Fredrikinkatu 61, 7th floor
Helsinki FIN-00100
Tel: +358 40 741 5505
david.sinclair@lightlake.fi
www.lightlake.fi

Great stuff!